Changchun High-Tech Industry Group Co Ltd
The company maintains a relatively strong liquidity position, with a current ratio of 3.76, indicating that it has sufficient current assets to cover its current liabilities. However, its free cash flow is negative at -2546299370.0 CNY, which suggests that the company is spending more on capital expenditures than it is generating in operating cash flow. The debt-to-equity ratio is 0.1, indicating a low level of leverage and a conservative capital structure. In terms of profitability, the company's return on equity is 0.007 and return on assets is 0.0052, which are relatively low compared to industry standards. This suggests that the company is not generating significant returns for its shareholders or effectively utilizing its assets. The operating income of 391776640.0 CNY and net income of 154971450.0 CNY indicate that the company is profitable, but the margins are thin. The company's revenue is primarily concentrated in its domestic market, with no significant international exposure disclosed. The revenue concentration in a single geographic region may pose a risk if the domestic market experiences economic downturns or regulatory changes. The company's revenue of 12083140490.0 CNY is derived from its pharmaceutical products, with no specific segments disclosed. The company's growth trajectory is uncertain, as there are no specific growth targets or projections provided. The capital expenditure of -2202738610.0 CNY indicates that the company is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive returns. The company's future revenue growth will depend on its ability to increase sales and improve operational efficiency. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital in the future. The company's conservative capital structure and low debt levels reduce the risk of financial distress, but the negative free cash flow may necessitate further financing. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's financial performance and strategic direction will be closely monitored by investors and analysts. The company's ability to maintain profitability and improve cash flow will be critical to its long-term success.
Business. Changchun High-Tech Industry Group Co Ltd develops and sells pharmaceutical products, primarily in China.
Classification. The company is classified in the Pharmaceuticals industry under the Healthcare economic sector with a confidence level of 0.92.
- The company has a strong current ratio but a negative free cash flow, indicating potential liquidity challenges.
- The company's return on equity and return on assets are low, suggesting inefficiencies in asset utilization and profitability.
- The company's revenue is concentrated in its domestic market, which may increase its exposure to local economic and regulatory risks.
- The company's capital expenditures are significant, but the negative free cash flow indicates that these investments are not yet generating positive returns.
- The company faces a medium liquidity risk and a low dilution risk, with a key flag of negative net cash after subtracting total debt.
- --
- # RATIONALES
- ```json
- Net cash is negative after subtracting total debt.